The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer

Wang, Yu; Huang, Zhao; Li, Bowen; Liu, Lin; Huang, Canhua

doi:10.3389/fendo.2022.863541

Cited by 10 publications

(8 citation statements)

References 207 publications

(181 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…showed that the application of epigenetic approaches for the diagnosis, clinical treatment, and prognosis of OC is a promising area for future clinical research 307–310 . New evidence suggests that epigenetic changes have important implications in OC drug resistance 311,312 . Abbosh et al.…”

Section: Abnormal Expression Of Histone‐modifying Enzymes and Human C...mentioning

confidence: 99%

“…[307][308][309][310] New evidence suggests that epigenetic changes have important implications in OC drug resistance. 311,312 Abbosh et al found that inhibiting H3K27 methylation re-sensitizes drug-resistant OC cells to cisplatin. 313 Moreover, loss of H3K27me3 can increase the expression of tumor suppressor genes, thereby leading to the occurrence of tumors.…”

Section: Ovarian Cancer (Oc)mentioning

confidence: 99%

“… 307 , 308 , 309 , 310 New evidence suggests that epigenetic changes have important implications in OC drug resistance. 311 , 312 Abbosh et al. found that inhibiting H3K27 methylation re‐sensitizes drug‐resistant OC cells to cisplatin.…”

Section: Abnormal Expression Of Histone‐modifying Enzymes and Human C...mentioning

confidence: 99%

See 2 more Smart Citations

Post‐translational modifications of histones: Mechanisms, biological functions, and therapeutic targets

Liu

Guo

et al. 2023

MedComm

View full text Add to dashboard Cite

Histones are DNA‐binding basic proteins found in chromosomes. After the histone translation, its amino tail undergoes various modifications, such as methylation, acetylation, phosphorylation, ubiquitination, malonylation, propionylation, butyrylation, crotonylation, and lactylation, which together constitute the “histone code.” The relationship between their combination and biological function can be used as an important epigenetic marker. Methylation and demethylation of the same histone residue, acetylation and deacetylation, phosphorylation and dephosphorylation, and even methylation and acetylation between different histone residues cooperate or antagonize with each other, forming a complex network. Histone‐modifying enzymes, which cause numerous histone codes, have become a hot topic in the research on cancer therapeutic targets. Therefore, a thorough understanding of the role of histone post‐translational modifications (PTMs) in cell life activities is very important for preventing and treating human diseases. In this review, several most thoroughly studied and newly discovered histone PTMs are introduced. Furthermore, we focus on the histone‐modifying enzymes with carcinogenic potential, their abnormal modification sites in various tumors, and multiple essential molecular regulation mechanism. Finally, we summarize the missing areas of the current research and point out the direction of future research. We hope to provide a comprehensive understanding and promote further research in this field.

show abstract

Section: Abnormal Expression Of Histone‐modifying Enzymes and Human C...mentioning

confidence: 99%

Section: Ovarian Cancer (Oc)mentioning

confidence: 99%

See 1 more Smart Citation

Post‐translational modifications of histones: Mechanisms, biological functions, and therapeutic targets

Liu

Guo

et al. 2023

MedComm

View full text Add to dashboard Cite

show abstract

“…DNA methylation is not the only epigenetic mechanism involved in carcinogenesis. Histone modifications and chromatin packaging play an important role in genome regulation in cancers [ 72 ]. In ovarian cancer specifically, histone marks such as the repressive H3K27me3 mark and active H3K4me3 mark are considered markers of bivalent genes, poised to be silenced during drug resistance in ovarian cancers, particularly regulated by the EZH2 protein complex [ 73 ].…”

Section: Epigenetic Changes Induced By Cocpmentioning

confidence: 99%

An epigenetic hypothesis for ovarian cancer prevention by oral contraceptive pill use

Avramenko,

Flanagan

2023

Clin Epigenet

View full text Add to dashboard Cite

Background Ovarian cancer is the second most common gynecological cancer type after uterine cancers. In 2020, according to worldwide statistics, there were more than 313,000 new cases of ovarian cancer. Most concerning with ovarian cancer is the poor overall survival, with only 30% of patients surviving for longer than 5 years after diagnosis. The reason for this poor outcome includes late diagnosis due to non-specific symptoms and a lack of any highly effective biomarkers of the early stages of ovarian carcinogenesis. However, it is important to note that some modifiable lifestyle factors can be preventative [pregnancy, breastfeeding and combined oral contraceptives pill (COCP) use]. Results There is now increasing data reporting the role of epigenetic changes, which are detectable in ovarian cancer tumors, suggesting the possibility that epigenetics may also play a key role in the mechanism of long-term effective prevention of ovarian cancer. To our knowledge, there is a lack of high-quality data on the molecular mechanisms of ovarian cancer prevention, although several hypotheses have been proposed. Conclusions This review focusses on the evidence for a proposed novel hypothesis—that COCPs act as a chemoprevention through the impact on the epigenome of the cells of origin of ovarian cancer—fallopian tubes epithelium.

show abstract

“…Genetic mutations have been reported to associate with ovarian cancer progression, such as BRCA1 (breast cancer 1) mutation and BRCA2 (breast cancer 2) mutation ( Sanchez-Lorenzo et al, 2022 ). Moreover, epigenetic regulation has been revealed to participate in the development of ovarian cancer ( Wang et al, 2022a ; Zhao et al, 2022 ). It is known that epigenetics refers to heritable changes and do not change DNA sequence.…”

Section: Introductionmentioning

confidence: 99%

The role of circRNAs in regulation of drug resistance in ovarian cancer

Zhan,

Li,

Lin

et al. 2023

Front. Genet.

View full text Add to dashboard Cite

Ovarian cancer is one of the female reproductive system tumors. Chemotherapy is used for advanced ovarian cancer patients; however, drug resistance is a pivotal cause of chemotherapeutic failure. Hence, it is critical to explore the molecular mechanisms of drug resistance of ovarian cancer cells and to ameliorate chemoresistance. Noncoding RNAs (ncRNAs) have been identified to critically participate in drug sensitivity in a variety of human cancers, including ovarian cancer. Among ncRNAs, circRNAs sponge miRNAs and prevent miRNAs from regulation of their target mRNAs. CircRNAs can interact with DNA or proteins to modulate gene expression. In this review, we briefly describe the biological functions of circRNAs in the development and progression of ovarian cancer. Moreover, we discuss the underneath regulatory molecular mechanisms of circRNAs on governing drug resistance in ovarian cancer. Furthermore, we mention the novel strategies to overcome drug resistance via targeting circRNAs in ovarian cancer. Due to that circRNAs play a key role in modulation of drug resistance in ovarian cancer, targeting circRNAs could be a novel approach for attenuation of chemoresistance in ovarian cancer.

show abstract

The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer

Cited by 10 publications

References 207 publications

Post‐translational modifications of histones: Mechanisms, biological functions, and therapeutic targets

Post‐translational modifications of histones: Mechanisms, biological functions, and therapeutic targets

An epigenetic hypothesis for ovarian cancer prevention by oral contraceptive pill use

The role of circRNAs in regulation of drug resistance in ovarian cancer

Contact Info

Product

Resources

About